Drug of choice in the management of hypertension in diabetes and diabetic nephropathy: angiotensin-converting enzyme inhibitors.
| Autor: | Ritz E; Division of Nephrology, Department of Internal Medicine, Nierenzentrum, Heidelberg, Germany. Prof.E.Ritz@t-online.de |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of clinical hypertension (Greenwich, Conn.) [J Clin Hypertens (Greenwich)] 2011 Apr; Vol. 13 (4), pp. 285-9. |
| DOI: | 10.1111/j.1751-7176.2011.00448.x |
| Abstrakt: | Hypertension is common in patients with diabetes mellitus and is a main cause of renal and cardiovascular complications. There has been recent controversy on what should be considered the optimal blood pressure goal and the optimal antihypertensive agent. It has become apparent that one blood pressure does not fit all in diabetic patients. Major confounders are preexisting cardiovascular disease and presence or absence of proteinuric kidney disease. In proteinuric diabetic nephropathy, renin-angiotensin system blockade is clearly indicated, but monotherapy is practically always insufficient to achieve target blood pressure values. (© 2011 Wiley Periodicals, Inc.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|